Renin-Angiotensin System and AtrialFibrillation:Understanding the Connection

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) involves triggers, perpetuators, and substrate, with recurrence linked to atrial remodeling.
• Atrial remodeling alters electrical, mechanical, and structural properties, creating a substrate conducive to AF.
• The renin-angiotensin-aldosterone system (RAAS) is a key target for therapies aimed at reducing atrial remodeling and treating AF.

Purpose of the Study:

• To review experimental and clinical evidence on the efficacy of RAAS inhibitors in treating AF.
• To evaluate the role of RAAS inhibitors in both primary and secondary prevention of AF.

Main Methods:

• Systematic review and meta-analysis of experimental and clinical studies.
• Analysis of randomized, placebo-controlled trials investigating RAAS inhibitors for AF prevention and treatment.

Main Results:

• RAAS inhibitors reduce new-onset AF risk in patients with congestive heart failure and left ventricular dysfunction.
• Evidence for RAAS inhibitors in primary prevention for hypertensive and post-myocardial infarction patients is less clear.
• Large trials of angiotensin II-receptor blockers for secondary AF prevention have yielded negative results.

Conclusions:

• RAAS inhibitors are effective in primary prevention of AF in specific heart failure populations.
• The use of RAAS inhibitors as antiarrhythmic drugs for AF prevention is decreasing due to negative trial outcomes.
• RAAS inhibitors remain a relevant strategy for AF management in patients with congestive heart failure.